Alexandru Stieber/LinkedIn
Dec 18, 2025, 13:34
Alexandru Stieber Explores VEXAS Syndrome
Alexandru Stieber, Internal Medicine Resident at SUUMC Bucharest, shared on LinkedIn:
”Second set of scientific updates from the SNFMI Congress that took place last week in Tours, France.
The theme of today’s post revolves around VEXAS syndrome, new implications for patients with a VEXAS-like phenotype and the evolving concept of “clonal hematopoiesis of immunological significance” (CHIS).
- proven efficacy of azacitidine treatment in VEXAS patients, even in the absence of myelodysplastic syndrome
- proven pathophysiology of UBA1 mutated myeloid cells that drive an inflammatory millieu which alters normal hematopoiesis
- new links found between clonalhematopoiesis with IDH mutations and inflammatory manifestations (polymyalgia rheumatica and large-vessel vasculitis), with resolution under targeted inhibitors”
Stay updated with Hemostasis Today.
-
Apr 10, 2026, 01:19Heghine Khachatryan: When Vascular Fragility Defines Risk – Rethinking Hemostasis in LDS
-
Apr 9, 2026, 21:39Mechanisms of Immune Dysregulation in Immune Thrombocytopenia – JTH
-
Apr 9, 2026, 21:37Arun V J: The Nation Inside the Human Body and Blood Function
-
Apr 9, 2026, 21:36José Antonio García Erce: Fall of While Blood Donation And Apheresis Growth in Spain
-
Apr 9, 2026, 21:34Chokri Ben Lamine: High-Yield Clinical Insights on Carfilzomib-Induced aHUS
-
Apr 9, 2026, 21:29Satyam Arora: Improving Thalassaemia Care in India Through Ground-Level Data
-
Apr 9, 2026, 20:33Pat Garcia-Gonzalez: On World Health Day, I’m thinking about what ‘health’ really means
-
Apr 9, 2026, 19:13Jan Sloves: Patterns and Pitfalls Influencing Treatment of Small Saphenous Vein Reflux
-
Apr 9, 2026, 18:38Jecko Thachil: Why D-dimers are Useful Tests for the Exclusion of Thromboembolism and the Diagnosis of DIC